The Weekly Mind Reader: IV Ketamine Shows Longer-Term Efficacy

The Journal of Clinical Psychiatry just released new data that shows that ketamine once again offers a ray of hope for veterans suffering from depression.

Clinical Outcomes of IV Ketamine for Depression

Short-term clinical trials found intravenous (IV) ketamine to be effective in reducing depressive symptoms. This study assessed longer-term outcomes of IV ketamine for depression and explored treatment and patient factors that may affect results.

Records of IV ketamine infusions for depression and associated Patient Health Questionnaire-9 (PHQ-9) scores were identified from Veterans Health Administration (VA) electronic medical records for patients treated in Fiscal Year 2020 and up to 12 months following the date of their first infusion.

And while only a minority of patients treated with IV ketamine for depression experienced response or remission, symptom improvements achieved within the first 6 weeks were sustained over at least 6 months with decreasing infusion frequency. Further study is needed to determine optimal infusion frequency and potential for adverse effects with repeated ketamine infusions for depression.

IN OTHER PSYCHIATRY AND NEUROLOGY NEWS

Dutch researchers discover five distinct subtypes of Alzheimer’s disease based on molecular characteristics and risk profiles.
Dutch scientists have successfully grown 3D mini-brains from human fetal brain tissue, which can self-organize in a dish.
A UNC study reveals that infants with enlarged perivascular spaces in the brain, caused by excess cerebrospinal fluid, have a 2.2 times greater chance of developing autism.
Stanford researchers discovered that ibogaine produces significant improvements in PTSD, depression, and anxiety among veterans with traumatic brain injuries.